Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,155 | 5 | 85.4% |
| Travel and Lodging | $1,027 | 6 | 6.2% |
| Food and Beverage | $717.98 | 7 | 4.3% |
| Education | $682.81 | 23 | 4.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $7,714 | 5 | $0 (2017) |
| GENZYME CORPORATION | $3,522 | 2 | $0 (2017) |
| Clovis Oncology, Inc. | $1,654 | 2 | $0 (2018) |
| HRA Pharma Rare Diseases | $1,500 | 1 | $0 (2020) |
| Aptevo Therapeutics Inc | $1,000 | 1 | $0 (2021) |
| Exelixis Inc. | $877.57 | 25 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $292.39 | 4 | $0 (2017) |
| Tempus AI, Inc | $23.87 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65.07 | 2 | Exelixis Inc. ($41.20) |
| 2022 | $82.40 | 2 | Exelixis Inc. ($82.40) |
| 2021 | $1,330 | 9 | Aptevo Therapeutics Inc ($1,000) |
| 2020 | $1,640 | 5 | HRA Pharma Rare Diseases ($1,500) |
| 2019 | $84.30 | 1 | Exelixis Inc. ($84.30) |
| 2018 | $1,654 | 2 | Clovis Oncology, Inc. ($1,654) |
| 2017 | $11,728 | 20 | Novartis Pharmaceuticals Corporation ($7,714) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/06/2024 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 02/22/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $23.87 | General |
| 03/10/2022 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $41.20 | General |
| Category: Oncology | ||||||
| 01/11/2022 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $41.20 | General |
| Category: Oncology | ||||||
| 11/22/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 10/15/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 10/07/2021 | Aptevo Therapeutics Inc | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/01/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 07/07/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 06/03/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 04/29/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 04/29/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 02/26/2021 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 11/18/2020 | HRA Pharma Rare Diseases | Lysodren (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Inoperable adrenal cortical carcinoma | ||||||
| 11/10/2020 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 10/02/2020 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 03/09/2020 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 01/17/2020 | Exelixis Inc. | — | Education | In-kind items and services | $16.48 | General |
| 02/15/2019 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $84.30 | General |
| 06/01/2018 | Clovis Oncology, Inc. | Rubraca (Drug) | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| Category: Oncology | ||||||
| 06/01/2018 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $153.69 | General |
| Category: Oncology | ||||||
| 11/07/2017 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $9.24 | General |
| Category: Oncology | ||||||
| 10/25/2017 | Exelixis Inc. | Cabometyx (Drug) | Education | In-kind items and services | $9.24 | General |
| Category: Oncology | ||||||
| 10/11/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Consulting Fee | Cash or cash equivalent | $3,439.00 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $83.10 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 217 | 574 | $259,845 | $40,444 |
| 2022 | 2 | 223 | 643 | $277,921 | $45,163 |
| 2021 | 2 | 204 | 656 | $257,058 | $47,598 |
| 2020 | 2 | 219 | 648 | $240,134 | $38,248 |
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 181 | 538 | $238,908 | $36,887 | 15.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $20,937 | $3,557 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 196 | 616 | $258,640 | $41,738 | 16.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 27 | 27 | $19,281 | $3,425 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 185 | 637 | $243,705 | $45,192 | 18.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $13,353 | $2,406 | 18.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 192 | 621 | $221,725 | $34,729 | 15.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 27 | 27 | $18,409 | $3,519 | 19.1% |
About Dr. Omer Kucuk, MD
Dr. Omer Kucuk, MD is a Internal Medicine healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255388948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Omer Kucuk, MD has received a total of $16,583 in payments from pharmaceutical and medical device companies, with $65.07 received in 2024. These payments were reported across 41 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($14,155).
As a Medicare-enrolled provider, Kucuk has provided services to 863 Medicare beneficiaries, totaling 2,521 services with total Medicare billing of $171,453. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Atlanta, GA
- Active Since 05/28/2006
- Last Updated 08/27/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1255388948
Products in Payments
- VOTRIENT (Drug) $7,278
- JEVTANA (Drug) $3,522
- Rubraca (Drug) $1,654
- Lysodren (Drug) $1,500
- AFINITOR (Drug) $436.00
- NO PRODUCT DISCUSSED (Drug) $292.39
- Cabometyx (Drug) $171.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Atlanta
Dr. Nitin Gupta, M.d, M.D
Internal Medicine — Payments: $1.2M
Dr. Zandraetta Tims-Cook, Md, Mph, MD, MPH
Internal Medicine — Payments: $648,799
Brian Pearlman, Md, MD
Internal Medicine — Payments: $588,483
Tracey Henry
Internal Medicine — Payments: $304,663
Michael Lloyd, Md, MD
Internal Medicine — Payments: $276,236
Mr. Robert Springer, M.d, M.D
Internal Medicine — Payments: $243,195